BridgeBio Pharma, Inc. (BBIO) stock
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$74.95+4.22 (+5.97%)
Close on Oct 30, 2026Market cap $14.65BP/E –Yield –
Earnings
BridgeBio Pharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 23, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$353.20M
+192.6% on a year earlier
EPS, Q3 FY2026
-$0.42
-$0.95 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of BridgeBio Pharma's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 23, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 29, 2026after the close | $353.20M | +192.6% | -$0.42 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 10, 2026after the close | $243.70M | +120.3% | -$0.78 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026after the close | $194.50M | +66.8% | -$0.84 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 24, 2026after the close | $154.20M | +2513.6% | -$1.00 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 29, 2025after the close | $120.70M | +4370.4% | -$0.95 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025after the close | $110.60M | +4927.3% | – | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 29, 2025after the close | $116.60M | -44.8% | -$0.88 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 20, 2025before the open | $5.90M | +247.1% | -$1.40 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | $2.70M | -34.1% | -$0.86 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 1, 2024before the open | $2.20M | +37.5% | -$0.39 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024before the open | $211.10M | +11460.8% | -$0.20 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 22, 2024before the open | $1.70M | -9.1% | -$0.96 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023before the open | $4.10M | +1113.0% | -$1.08 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023before the open | $1.60M | -97.8% | -$0.98 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023before the open | $1.83M | +7.8% | -$0.92 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 23, 2023before the open | $1.87M | -85.5% | -$0.92 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022after the close | $338.00K | -85.6% | -$0.93 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022after the close | $73.75M | – | -$0.07 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022after the close | $1.69M | – | -$1.35 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022before the open | $12.89M | – | -$1.01 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021before the open | $2.34M | – | -$1.06 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 13, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 14, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 26, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
BridgeBio Pharma has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When BridgeBio Pharma puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases BridgeBio Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- News
- News
- Results
- News
- Update
- News
- News
- Results
- News
- Results
- News
- News